Skip to content

Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia

Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia: The Glu-FX Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03184064
Acronym
Glu-FX
Enrollment
32
Registered
2017-06-12
Start date
2017-05-30
Completion date
2018-06-01
Last updated
2018-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Period

Keywords

Blackcurrant, Citrus, Polyphenols, Glucose, Postprandial, Metabolism

Brief summary

Large postprandial glucose responses are associated with increased risk of chronic diseases, including diabetes and cardiovascular disease. Our group have previously shown that fruit polyphenol extracts, when consumed immediately before a mixed carbohydrate meal, reduce postprandial glycaemia. The aim of this study is to investigate the effects of a blackcurrant polyphenol extract and citrus polyphenol extract (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, and a combination of the two will have a greater effect.

Detailed description

Intake of carbohydrate-rich foods transiently increases blood glucose levels (known as postprandial glycaemia). Repeated high postprandial glucose responses are evidenced to dysregulate functional proteins, oxidative stress and pancreatic beta cell function; thus increasing the risk of diabetes and cardiovascular disease. Accordingly, meals that elicit a reduced, or more gradual, rise in blood glucose levels are desirable. Fruit polyphenols may help to limit the glucose excursion following a high carbohydrate meal. Previous research by our group has demonstrated that blackcurrant polyphenols significantly inhibited the average incremental area under the curve (T+0 to +30 min) of plasma glucose. Possible mechanisms include inhibition of intestinal enzymes and inhibition of intestinal glucose absorption by decreasing Sodium-glucose linked transporter 1 (SGLT-1) / Glucose transporter 2 (GLUT-2) glucose transporter activity. In vitro data suggests that citrus polyphenols may impact on carbohydrate metabolism by binding to starch molecules, however, effects on postprandial glycaemia are not yet known. Blackcurrants and citrus fruits have distinct polyphenol profiles and may therefore act on glucose homeostasis via different mechanisms. Blackcurrants are rich in anthocyanins and flavanols, whereas citrus fruits are rich in flavanones, hesperetin and naringenin. Theoretically, combining blackcurrant with citrus extracts may have synergistic effects. The aim of this study is to investigate the effects of blackcurrant polyphenol extracts and citrus polyphenol extracts (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, a combination of the two will have a greater effect. Study design: A randomised, controlled, double-blind, cross-over study will be conducted. Subjects will consume different drinks at 4 separate study visits. Drinks will contain either: blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose), blackcurrant and citrus extract (low dose + low dose), or placebo (no polyphenols). The study will utilise an incomplete block design. Subjects will consume the placebo drink and 3 out of 4 of the polyphenol-containing drinks during the study. At least a 7-day wash-out period will be required between study days. Baseline (fasted) blood samples will be taken in duplicate at T-10 min and T-5 min before consuming the test drink (T+0 min). Immediately following consumption of the drink, a mixed carbohydrate test meal will be consumed. Further blood samples will be collected at 10 min intervals for the first 30 min and then every 15 min until T+90 min and at T+120 min. Blood samples will be analysed for plasma glucose, insulin, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), C-peptide and nonesterified fatty acids (NEFA).

Interventions

DIETARY_SUPPLEMENTBlackcurrant extract (low dose)

Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.

DIETARY_SUPPLEMENTPlacebo

Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.

DIETARY_SUPPLEMENTCitrus extract (low dose)

Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.

DIETARY_SUPPLEMENTBlackcurrant extract (high dose)

Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.

DIETARY_SUPPLEMENTBlackcurrant and citrus extracts (low dose / low dose)

Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.

Sponsors

King's College London
CollaboratorOTHER
Lucozade Ribena Suntory
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Incomplete block cross-over design. Each participant receives placebo plus 3 out of 4 active treatments.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 18-70 years * Men and women * Healthy (free of diagnosed diseases listed in the

Exclusion criteria

) * Body Mass Index 18-35 kg/m2 * Able to understand the information sheet and willing to comply with study protocol * Able to give informed written consent

Design outcomes

Primary

MeasureTime frameDescription
Postprandial glycaemia (iAUC 0-30 min)30 minThe primary endpoint is iAUC 0-30 min for plasma glucose concentrations

Secondary

MeasureTime frameDescription
Postprandial glycaemia: Tmax120 minTmax for plasma glucose concentrations
Postprandial non-esterified fatty acids (NEFA): iAUC 0-120 min120 miniAUC 0-120 min for serum NEFA concentrations
Postprandial blood peptide YY (PYY): iAUC 0-120 min120 miniAUC 0-120 minfor plasma PYY concentrations
Postprandial blood peptide YY (PYY): iCmax120 miniCmax for plasma PYY concentrations
Postprandial blood peptide YY (PYY): Tmax120 minTmax for plasma PYY concentrations
Postprandial blood peptide YY (PYY): Absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for plasma PYY concentrations
Postprandial glycaemia: iAUC 0-120 min120 miniAUC 0-120 min for plasma glucose concentrations
Postprandial glycaemia: absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for plasma glucose concentrations
Postprandial insulinemia: iAUC 0-30 min30 miniAUC 0-30 min for serum insulin concentrations
Postprandial insulinemia: iAUC 0-120 min120 miniAUC 0-120 min for serum insulin concentrations
Postprandial insulinemia: iCmax120 miniCmax, for serum insulin concentrations
Postprandial insulinemia: Tmax120 minTmax for serum insulin concentrations
Postprandial insulinemia: absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for serum insulin concentrations
Postprandial C-peptide: iAUC 0-30 min30 miniAUC 0-30 min for plasma C-peptide concentrations
Postprandial C-peptide: iAUC 0-120 min30 miniAUC 0-120 min for plasma C-peptide concentrations
Postprandial C-peptide: iCmax120 miniCmax for plasma C-peptide concentrations
Postprandial C-peptide: Tmax120 minTmax for plasma C-peptide concentrations
Postprandial C-peptide: Absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for plasma C-peptide concentrations
Postprandial non-esterified fatty acids (NEFA): iAUC 0-30 min30 miniAUC 0-30 min for serum NEFA concentrations
Postprandial glycaemia: iCmax120 miniCmax for plasma glucose concentrations
Postprandial non-esterified fatty acids (NEFA): iCmax120 miniCmax for serum NEFA concentrations
Postprandial non-esterified fatty acids (NEFA): Tmax120 minTmax for serum NEFA concentrations
Postprandial non-esterified fatty acids (NEFA): Absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for serum NEFA concentrations
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-30 min30 miniAUC 0-30 min for plasma GIP concentrations
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-120 min120 miniAUC 0-120 min for plasma GIP concentrations
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iCmax120 miniCmax, for plasma GIP concentrations
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Tmax120 minTmax for plasma GIP concentrations
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for plasma GIP concentrations
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-30 min30 miniAUC 0-30 min for plasma GLP-1 concentrations
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-120 min120 miniAUC 0-120 min, for plasma GLP-1 concentrations
Postprandial blood Glucagon-like peptide 1 (GLP-1): iCmax120 miniCmax for plasma GLP-1 concentrations
Postprandial blood Glucagon-like peptide 1 (GLP-1): Tmax30 minTmax for plasma GLP-1 concentrations
Postprandial blood Glucagon-like peptide 1 (GLP-1): Absolute concentrations at specific time points120 minAbsolute concentrations at specific time points, for plasma GLP-1 concentrations
Postprandial blood peptide YY (PYY): iAUC 0-30 min30 miniAUC 0-30 min for plasma PYY concentrations

Other

MeasureTime frameDescription
VAS measures of the palatability of the study drink10 min following the test drinkDescriptive statistics
VAS measures of mood, satiety and digestive comfort120 minDescriptive statistics
Buccal mouth swabOne off sample, collected at screeningFuture exploratory analysis of lactase activity via the derived allele at the European lactase persistence (LP) locus
Food diary (estimated/unweighed)7-days, collected at screeningHabitual dietary intake analysis

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026